Indeed, GSK2636771, the potent, orally bioavailable, adenosine triphosphate-competitive and selective inhibitor of PI3Kβ, not only causes dose-dependent nausea (40%) and vomiting (31%) in cancer patients, but also reduces the phospho/total Akt ratio [26]. Here, AKT1 is linked to cancer.